title: Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease.
authors.affiliation: Inspire Pharmaceuticals, Durham, North Carolina, USA
authors.forename: Benjamin R
authors.initials: BR
authors.lastname: Yerxa
authors.forename: Mohan
authors.initials: M
authors.lastname: Mundasad
authors.forename: Robin N
authors.initials: RN
authors.lastname: Sylvester
authors.forename: JoAnn C
authors.initials: JC
authors.lastname: Garden
authors.forename: Mark
authors.initials: M
authors.lastname: Cooper
authors.forename: Donald J
authors.initials: DJ
authors.lastname: Kellerman
mesh_terms: D003941:Diagnostic Techniques, Ophthalmological; D015352:Dry Eye Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D005123:Eye / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D011122:Polyphosphates; D058910:Purinergic P2 Receptor Agonists; D058473:Receptors, Purinergic P2Y2; D012449:Safety; D012720:Severity of Illness Index; D016037:Single-Blind Method; D013997:Time Factors; D014500:Uracil Nucleotides
chemical_list: D009883:Ophthalmic Solutions; C546385:P2RY2 protein, human; D011122:Polyphosphates; D058910:Purinergic P2 Receptor Agonists; D058473:Receptors, Purinergic P2Y2; D014500:Uracil Nucleotides; C403315:diquafosol